{"url_path":"/sec/alzn/10-k/2026/item-13","section_key":"item-13","section_title":"Item 13 ****CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS AND DIRECTOR INDEPENDENCE**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1677077/0001214659-26-008832-index.html","accession_number":"0001214659-26-008832","cik":"0001677077","ticker":"ALZN","issuer_name":"Alzamend Neuro, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1677077/0001214659-26-008832-index.html","primary_entity_key":"0001677077","primary_entity_name":"Alzamend Neuro, Inc."},"word_count":479,"has_tables":true,"body_markdown":"** **\n\n**ITEM 13.****CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS AND DIRECTOR INDEPENDENCE**\n\n \n\n**Transactions with Related Persons**\n\n \n\nTo the best of our knowledge,\nduring our most recent fiscal year end on April 30, 2026, other than as set forth below, there were no material transactions, or\nseries of similar transactions, or any currently proposed transactions, or series of similar transactions, to which we were or are to\nbe a party, in which the amount involved exceeds $33,412, or 1% of the average total assets at year-end for the last two completed fiscal years,\nand in which any director or executive officer, or any security holder who is known by us to own of record or beneficially more than 5%\nof any class of our common stock, or any member of the immediate family of any of the foregoing persons, has an interest (other than compensation\nto our officers and directors in the ordinary course of business).\n\n \n\nOur accounting and finance\noffice is located in Orange County, California utilizing shared office space within the offices of HDI, a related party. Our legal office\nis located in New York, NY utilizing shared office space within the offices of HDI. We currently do not pay rent for our Orange County,\nCalifornia or New York, NY office spaces. \n\n \n\n**Future Transactions**\n\n \n\nOur Board has adopted a policy\nwhereby any future transactions between our company and any of our subsidiaries, affiliates, officers, directors, principal stockholders\nor any affiliates of the foregoing will be on terms no less favorable to us than could reasonably be obtained in “arm’s length”\ntransactions with independent third parties, and any such transactions will also be approved by a majority of our disinterested and independent\noutside directors.\n\n** **\n\n - 64 - \n\n \n\n** **\n\n**Director Independence**\n\n \n\n \n \nIndependent(1)\n \nAudit Committee\n \nNominating and\n\nGovernance Committee(2)\n \nCompensation Committee(3)\n\n**Director**\n \n \n \n \n \n \n \n \n\nStephan Jackman\n \nNo\n \n \n \n \n \n \n\nWilliam B. Horne\n \nYes\n \n X\n \n \n \n \n\nMilton C. Ault\n \nNo\n \n \n \n \n \n \n\nHenry Nisser\n \nNo\n \n \n \n \n \n \n\nMark Gustafson\n \nYes\n \nC\n \n \n \nX\n\nJeffrey Oram\n \nYes\n \nX\n \nC\n \nX\n\n \n\n____________\n\nC – Chairman of committee\n\nX – Member of committee\n\n \n\n(1)Dr. McGrath, who passed away on July 20, 2026, was an independent member of the board of directors. As\na result of her passing, the board of directors does not currently consist of a majority of independent directors. Under Nasdaq rules,\nwe have until the earlier of (i) our next annual stockholders meeting or (ii) one year from the occurrence of the event that caused the\nfailure to comply with the requirement to have a majority of independent directors. Our board of directors will appoint a new independent\ndirector in due time.\n\n(2)Dr. McGrath was a member of the nominating and governance committee. Our board of directors will appoint\na new member in due time.\n\n(3)There is currently no chairman of the compensation committee. Dr. McGrath was the chairman of the compensation\ncommittee. Our board of directors will appoint a new chairman in due time."}